FoxP3+ CD8 T-cells Suppress Bone Loss via Osteoclast Feedback Loop
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bone-loss and inflammation-based diseases, such as osteoporosis and rheumatoid arthritis, are limited in effectiveness and safety, as they either fail to directly address bone loss or come with severe adverse reactions, and existing therapies do not effectively modulate both bone resorption and inflammation.
Innovation Solution
A bi-directional regulatory loop between osteoclasts and FoxP3+ CD8 T-cells is established through cell-based therapies or biologics, where osteoclasts induce FoxP3+ CD8 T-cells to regulate osteoclast function, thereby suppressing bone loss and inflammation, using methods like culturing blood cells with M-CSF and RANKL or administering low-dose RANK agonists to induce TcREG cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If anti-inflammatory agents (NSAIDs, steroids, biologics) are used to treat bone-loss diseases, then inflammation is reduced, but bone loss is not directly addressed and severe adverse reactions occur
Solution Approach 1:
The patent introduces FoxP3+ CD8 T-cells as intermediary regulatory cells that mediate between the immune system and bone metabolism. These TcREG cells receive signals from osteoclasts via RANKL and in turn suppress osteoclast activity, creating a bidirectional regulatory loop that simultaneously addresses inflammation and bone loss without the severe side effects of conventional anti-inflammatory agents
Solution Approach 2:
The patent establishes a feedback mechanism where osteoclasts signal to FoxP3+ CD8 T-cells through RANKL, and these T-cells subsequently provide negative feedback to suppress osteoclast activity. This closed-loop regulatory system naturally balances inflammation and bone resorption, improving safety while maintaining therapeutic efficacy
2Loss of substance
If bisphosphonates are used to inhibit osteoclasts, then bone loss is slowed, but osteonecrosis of the jaw and increased fracture risk occur
Solution Approach 1:
The patent enables the immune system to self-regulate bone metabolism through the activation of FoxP3+ CD8 T-cells by osteoclasts. This self-service mechanism naturally suppresses excessive osteoclast activity and bone loss while maintaining bone health and avoiding the harmful effects of pharmacological suppression
Solution Approach 2:
FoxP3+ CD8 T-cells serve as intermediary cells that translate osteoclast signals into regulatory responses. Rather than directly inhibiting osteoclasts with drugs like bisphosphonates, the patent uses these T-cells as intermediaries to achieve gentle, physiological suppression that avoids osteonecrosis and fracture risks
3Productivity
If RANKL is used to stimulate osteoclasts, then bone resorption increases, but excessive bone loss occurs without adequate immune regulation
Solution Approach 1:
The patent creates a feedback loop where RANKL stimulation of osteoclasts is naturally regulated by the resulting FoxP3+ CD8 T-cell response. The osteoclasts that are activated by RANKL subsequently induce TcREG cells, which then suppress further osteoclast activity, preventing excessive bone loss while maintaining necessary bone resorption for homeostasis
Data Source
AI summary
Systems and methods for inhibiting bone loss using FoxP3+ CD8 T-cells (TcREG). Osteoclasts are induced to produce FoxP3+ CD8 T-cells (TcREG) either in vivo or ex vivo. The FoxP3+ CD8 T-cells (TcREG) are provided to the patient to subsequently regulate osteoclast function, thereby establishing a bi-directional regulatory loop between osteoclasts and FoxP3+ CD8 T-cells (TcREG).